title: Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial.
abstract: Longitudinal studies with very long follow-up periods of patients with obsessive-compulsive disorder (OCD) who have received adequate treatment are rare. In the current study, 30 of 37 inpatients (81%) with severe OCD were followed up 6-8 years after treatment with cognitive-behavioral therapy (CBT) in combination with either fluvoxamine or placebo in a randomized design. The significant improvements (with large effectsizes) in obsessive-compulsive symptoms from pre- to post-treatment (41% reduction on the Y-BOCS) remained stable at follow-up (45 %). Responder rates, defined as > or = 35% reduction on the Y-BOCS, were 67% and 60%, respectively. Depressive symptoms decreased significantly not only from pre- to post-treatment but also during follow-up. Re-hospitalization, which occurred in 11 patients (37 %), was associated with more severe depressive symptoms at pre-treatment and living without a partner. Full symptom remission at follow-up, defined as both Y-BOCS total score < or = 7 and no longer meeting diagnostic criteria for OCD, was achieved by 8 patients (27 %). Patients without full remission at follow-up had a significantly longer history of OCD, assessed at pretreatment, compared to remitted patients. The shortterm treatment outcome had no predictive value for the long-term course. Throughout the naturalistic follow-up, nearly all patients (29 patients) received additional psychotherapy and/or medication. This might indicate that such chronic OCD patients usually need additional therapeutic support after effective inpatient treatment to maintain their improvements over long periods.
authors.affiliation: University Hospital of Hamburg, Centre of Psychosocial Medicine, Dept. of Psychiatry and Psychotherapy , Hamburg. michael.rufer@usz.ch
authors.forename: Michael
authors.initials: M
authors.lastname: Rufer
authors.forename: Iver
authors.initials: I
authors.lastname: Hand
authors.forename: Heike
authors.initials: H
authors.lastname: Alsleben
authors.forename: Anne
authors.initials: A
authors.lastname: Braatz
authors.forename: Jürgen
authors.initials: J
authors.lastname: Ortmann
authors.forename: Birgit
authors.initials: B
authors.lastname: Katenkamp
authors.forename: Susanne
authors.initials: S
authors.lastname: Fricke
authors.forename: Helmut
authors.initials: H
authors.lastname: Peter
mesh_terms: D000328:Adult; D017668:Age of Onset; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D015928:Cognitive Behavioral Therapy; D003131:Combined Modality Therapy; D003866:Depressive Disorder / Q000150:complications / Q000523:psychology; D004311:Double-Blind Method; D004651:Employment; D005260:Female; D016666:Fluvoxamine / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008393:Marriage; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy / Q000523:psychology / Q000628:therapy*; D012959:Socioeconomic Factors; D016896:Treatment Outcome
chemical_list: D018687:Antidepressive Agents, Second-Generation; D016666:Fluvoxamine